Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

Abstract

Long-term treatment with long-acting risperidone may be associated with improvement to adherence to therapy and quality of life. Patients may show improvement in psychopathological symptoms, subjective well-being and quality of life.

Effective strategies for nurses empowering the life quality and antipsychotic adherence of patients with schizophrenia

“…However, the results displayed no statistically significant relationship between the life quality and medication compliance, may be attributed to the small sample size in the present study. This result is similar to a study carried out by Niolu [30] identified an important role that has been assigned recently to the notion of subjective well-being and life quality, even in patients submitted to antipsychotic drugs.…”

Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study

“…Available evidence on subjective experience of AMT mainly relies on studies on oral therapy and underlines a better tolerability of second-generation antipsychotics (SGA) over first-generation antipsychotics (FGA) [18]. Moreover, SGA-LAIs seem to be associated with better subjective experience compared to first-generation depot formulations [24,25]. Although patients' attitude towards LAIs before their use is often influenced by negative beliefs about this formulation [26][27][28], only a few studies evaluated the impact of switching to a SGA-LAI on PROs [29][30][31][32][33][34][35][36].…”

LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment

“…Not surprisingly, LAI-AMT have been shown to reduce relapse and hospitalization rates, compared with oral-AMT [5,[20][21][22]. However, although a growing interest in subjective recovery from schizophrenia is developing in the scientific community, only a few studies have been devoted to the differences between LAI and oral AMT in terms of patient's subjective experience of treatment [14,18,[23][24][25][26][27][28]. Moreover, the fact that the ''pre-post'' or ''mirror image'' design of the available real-world studies on this topic implies the lack of a control group may represent a serious methodological limitation of this source of evidence [29][30][31].…”